Sarit Assouline

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos et al. · The Lancet Oncology · 2020 · 587 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Phase I clinical trial of i.v. ascorbic acid in advanced malignancy

L. John Hoffer, Mark Levine, Sarit Assouline et al. · Annals of Oncology · 2008 · 372 citations · Full text

Medicine, Oncology, Pharmacology +5

Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas

Ryan D. Morin, Sarit Assouline, Miguel Alcaide et al. · Clinical Cancer Research · 2015 · 227 citations

Life Sciences, Genetics, Molecular Genetics +14

The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation

Hiba Ahmad Zahreddine, Biljana Culjkovic‐Kraljacic, Sarit Assouline et al. · Nature · 2014 · 181 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +10

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma

Sarit Assouline, Torsten Holm Nielsen, Stephen Yu et al. · Blood · 2016 · 140 citations · Full text

Medicine, Hematology, Oncology +9